| 000 | 01530 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513074120.0 | ||
| 264 | 0 | _c19931012 | |
| 008 | 199310s 0 0 eng d | ||
| 022 | _a0936-3076 | ||
| 024 | 7 |
_a10.1007/BF02257674 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHeinonen, E H | |
| 245 | 0 | 0 |
_aEffects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. _h[electronic resource] |
| 260 |
_bJournal of neural transmission. Parkinson's disease and dementia section _c1993 |
||
| 300 |
_a193-202 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlzheimer Disease _xcerebrospinal fluid |
| 650 | 0 | 4 |
_aBiogenic Monoamines _xcerebrospinal fluid |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aNorepinephrine _xcerebrospinal fluid |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 |
_aSelegiline _xadverse effects |
| 650 | 0 | 4 |
_aTryptophan _xcerebrospinal fluid |
| 700 | 1 | _aSavijärvi, M | |
| 700 | 1 | _aKotila, M | |
| 700 | 1 | _aHajba, A | |
| 700 | 1 | _aScheinin, M | |
| 773 | 0 |
_tJournal of neural transmission. Parkinson's disease and dementia section _gvol. 5 _gno. 3 _gp. 193-202 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02257674 _zAvailable from publisher's website |
| 999 |
_c8368373 _d8368373 |
||